Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Biomedicines ; 10(7)2022 Jul 08.
Article in English | MEDLINE | ID: mdl-35884947

ABSTRACT

Diabetes is the most common cause of end-stage renal disease, also called kidney failure. The link between the renal artery receptor angiotensin II type I (AT1R) and endothelin-1 (ET-1), involved in vasoconstriction, oxidative stress, inflammation and kidney fibrosis (collagen) in diabetes-induced nephropathy with and without metformin incorporation has not been previously studied. Diabetes (type 2) was induced in rats and another group started metformin (200 mg/kg) treatment 2 weeks prior to the induction of diabetes and continued on metformin until being culled at week 12. Diabetes significantly (p < 0.0001) modulated renal artery tissue levels of AT1R, ET-1, inducible nitric oxide synthase (iNOS), endothelial NOS (eNOS), and the advanced glycation end products that were protected by metformin. In addition, diabetes-induced inflammation, oxidative stress, hypertension, ketonuria, mesangial matrix expansion, and kidney collagen were significantly reduced by metformin. A significant correlation between the AT1R/ET-1/iNOS axis, inflammation, fibrosis and glycemia was observed. Thus, diabetes is associated with the augmentation of the renal artery AT1R/ET-1/iNOS axis as well as renal injury and hypertension while being protected by metformin.

2.
J Cell Physiol ; 233(2): 1330-1341, 2018 Feb.
Article in English | MEDLINE | ID: mdl-28500758

ABSTRACT

The MSCs of various origins are known to ameliorate or modulate cell survival strategies. We investigated, whether UCB MSCs could improve the survival of the human neuronal cells and/or fibroblast assaulted with DPN sera. The results showed, the co-culture of UCB MSCs with human neuronal cells and/or fibroblasts could effectively scavenge the pro-inflammatory cytokines TNF-α, IL-1ß, IFN-ɤ and IL - 12 and control the pro-apoptotic expression of p53/Bax. Further co-culture of UCB MSCs have shown to induce anti-inflammatory cytokines like IL-4, IL-10 and TGF-ß and anti-apoptotic Bclxl/Bcl2 expression in the DPN sera stressed cells. Amelioration of elevated [Ca2+ ]i and cROS, the portent behind the NFκB/Caspase-3 mediated inflammation in DPN rescued the cells from apoptosis. The results of systemic administration of BM MSCs improved DPN pathology in rat as extrapolated from human cell model. The BM MSCs ameliorated prolonged distal motor latency (control: 0.70 ± 0.06, DPN: 1.29 ± 0.13 m/s DPN + BM MSCs: 0.89 ± 0.02 m/s, p < 0.05) and lowered high amplitude of compound muscle action potentials (CMAPs) (control: 12.36 ± 0.41, DPN: 7.52 ± 0.61 mV, DPN + MSCs: 8.79 ± 0.53 mV, p < 0.05), while slowly restoring the plasma glucose levels. Together, all these results showed that administration of BM or UCB MSCs improved the DPN via ameliorating pro-inflammatory cytokine signaling and [Ca2+ ]i homeostasis.


Subject(s)
Calcium/metabolism , Cord Blood Stem Cell Transplantation , Cytokines/metabolism , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Type 2/complications , Diabetic Neuropathies/surgery , Inflammation Mediators/metabolism , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells/metabolism , Neurons/metabolism , Peripheral Nerves/metabolism , Action Potentials , Animals , Apoptosis , Apoptosis Regulatory Proteins/metabolism , Blood Glucose/metabolism , Cells, Cultured , Coculture Techniques , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Type 2/blood , Diabetic Neuropathies/blood , Diabetic Neuropathies/etiology , Diabetic Neuropathies/physiopathology , Homeostasis , Humans , Male , Neural Conduction , Neurons/pathology , Oxidative Stress , Peripheral Nerves/pathology , Peripheral Nerves/physiopathology , Rats, Wistar , Reaction Time , Signal Transduction , Time Factors
3.
Curr Vasc Pharmacol ; 13(5): 658-69, 2015.
Article in English | MEDLINE | ID: mdl-25675330

ABSTRACT

Cardiovascular disease (CVD) is among the most major causes of morbidity and mortality worldwide. Great progress has been made in the management of CVD which has been influenced by the use of experimental animal models. These models provided information at cellular and molecular levels and allowed the development of treatment strategies. CVD models have been developed in many species, including large animals (e.g. pigs and dogs) and small animals (e.g. rats and mice). Although, no model can solely reproduce clinical HF, simulations of heart failure (HF) are available to experimentally tackle certain queries not easily resolved in humans. Induced HF may also be produced experimentally through myocardial infarction (MI), pressure loading, or volume loading. Volume loading is useful to look at hormone and electrolyte disturbances, while pressure loading models is helpful to study ventricular hypertrophy, cellular imbalance and vascular changes in HF. Coronary heart disease is assessed in MI animal models. In this review we describe various experimental models used to study the pathophysiology of HF.


Subject(s)
Disease Models, Animal , Heart Failure/physiopathology , Animals , Cardiomegaly/physiopathology , Coronary Disease/physiopathology , Heart Failure/therapy , Humans , Myocardial Infarction/physiopathology , Species Specificity
4.
Curr Pharm Des ; 17(33): 3699-712, 2011 Nov.
Article in English | MEDLINE | ID: mdl-22074439

ABSTRACT

The metabolic syndrome (MetS) is common, and its associated risk burdens of diabetes and cardiovascular disease (CVD) are a major public health problem. The hypothesis that main constituent parameters of the MetS share common pathophysiologic mechanisms provides a conceptual framework for the future research. Exercise and weight loss can prevent insulin resistance and reduce the risk of diseases associated with the MetS. Interrupting intracellular and extracellular reactive oxygen species (ROS) overproduction could also contribute to normalizing the activation of metabolic pathways leading to the onset of diabetes, endothelial dysfunction, and cardiovascular (CV) complications. On the other hand, it is difficult to counteract the development of CV complications by using conventional antioxidants. Indeed, interest has focused on strategies that enhance the removal of ROS using either antioxidants or drugs that enhance endogenous antioxidant defense. Although these strategies have been effective in laboratory experiments, several clinical trials have shown that they do not reduce CV events, and in some cases antioxidants have actually worsened the outcome. More research is needed in this field.


Subject(s)
Antioxidants/therapeutic use , Metabolic Syndrome/drug therapy , Dyslipidemias/etiology , Fatty Liver/metabolism , Fatty Liver/physiopathology , Humans , Hyperlipidemias/etiology , Hypertension/etiology , Hypertension/physiopathology , Inflammation/etiology , Inflammation/physiopathology , Insulin Resistance/physiology , Metabolic Syndrome/diet therapy , Metabolic Syndrome/metabolism , Metabolic Syndrome/physiopathology , Obesity/metabolism , Obesity/physiopathology , Obesity, Abdominal/metabolism , Obesity, Abdominal/physiopathology , Oxidative Stress/drug effects , Signal Transduction/drug effects , Thrombosis/etiology , Thrombosis/physiopathology
5.
Angiology ; 61(2): 145-56, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19939823

ABSTRACT

The role of vascular endothelial growth factor (VEGF) and erythropoietin (EPO) in mediating hypoxic preconditioning under the acute intermittent hypoxic condition (AIH) was investigated in this study. Male Wistar rats were randomly assigned and kept in normoxic conditions, (Nx) or in AIH conditions and subjected to brief cycles hypoxia/reoxygenation. Hearts were isolated, perfused, and subjected to in vitro global ischemia followed by reperfusion. During and at the end of reperfusion, left ventricular developed pressure (LVDP); LV end diastolic pressure (LVEDP); rate pressure product (RPP); peak left ventricular pressure rise (DeltaP/Deltat (max) ) and heart rate (HR) were measured. Hearts subjected to AIH displayed a significant higher LVDP (P < .001), RPP (P < .001), and DeltaP/Deltat ( max) (P < .001). Expression of VEGF and EPO were significantly increased at 3, 8, and 24 hours after AIH. Hypoxic training could provide a new approach to enhance endogenous cardioprotective mechanisms.


Subject(s)
Erythropoietin/physiology , Hypoxia/physiopathology , Ischemic Preconditioning, Myocardial , Myocardial Reperfusion Injury/physiopathology , Vascular Endothelial Growth Factor A/physiology , Adaptation, Physiological , Animals , Erythropoietin/metabolism , Immunohistochemistry , In Vitro Techniques , Male , Myocardial Reperfusion Injury/metabolism , Myocytes, Cardiac/metabolism , Rats , Rats, Wistar , Vascular Endothelial Growth Factor A/metabolism
6.
Curr Vasc Pharmacol ; 8(5): 661-72, 2010 Sep.
Article in English | MEDLINE | ID: mdl-19485907

ABSTRACT

Numerous studies have shown that increased oxidative stress (OxS) is present in diabetic patients. There is evidence that this OxS can be increased before complications associated with diabetes mellitus (DM) occur. However, the role and influence of OxS in the initiation and progression of DM remains the subject of debate. It has been suggested that in DM, OxS is caused by increased production of reactive oxygen species (ROS), and associated with reduction in antioxidant defenses and altered cellular redox status. Acute and chronic OxS which could enhance the development of complications associated with DM. This review considers recent findings on the role of antioxidants in controlling OxS and the incidence of DM with emphasis on animal and human studies.


Subject(s)
Antioxidants/physiology , Antioxidants/therapeutic use , Diabetes Mellitus/epidemiology , Diabetes Mellitus/physiopathology , Diabetic Angiopathies/prevention & control , Oxidative Stress , Animals , Diabetes Complications/epidemiology , Diabetes Complications/metabolism , Diabetes Complications/prevention & control , Diabetes Mellitus/metabolism , Diabetic Angiopathies/epidemiology , Diabetic Angiopathies/metabolism , Disease Progression , Humans , Oxidation-Reduction , Reactive Oxygen Species/metabolism
7.
J Diabetes Complications ; 23(2): 130-6, 2009.
Article in English | MEDLINE | ID: mdl-18436458

ABSTRACT

UNLABELLED: We investigated the possible role of reactive oxygen species (ROS) on renal function in experimental diabetes. MATERIALS AND METHODS: Seven groups of male rats were studied. Group I consisted of control animals. Diabetes was induced (by streptozotocin) in the animals in the other groups and they received either insulin or vitamin E (300 or 600 mg/kg), both insulin and vitamin E, or no treatment for 4 weeks. At the end of the study, blood pressure was measured and parameters of kidney function and oxidative stress were evaluated in serum and kidney tissue samples. RESULTS: Diabetic animals had higher blood pressures; increased serum glucose, urea, creatinine, cyclic guanosine monophosphate (cGMP); increased kidney tissue levels of malondialdehyde and inducible nitric oxide synthetase (iNOS); and reduced serum glutathione peroxidase when compared with control animals. Blood glucose levels in diabetic animals were controlled by insulin and not by any dose of vitamin E alone. However, all other measured parameters improved towards control levels with either insulin or vitamin E in either dose. An additive beneficial effect was observed on the levels of iNOS and cGMP when both forms of treatment were used in diabetic animals. CONCLUSIONS: We conclude that ROS may play an important role in diabetes-induced nephropathy in this rat model. Vitamin E supplementation in addition to insulin can have additive protective effects against deterioration of renal function in this model.


Subject(s)
Diabetes Mellitus, Experimental/physiopathology , Kidney/physiopathology , Oxidative Stress/physiology , Vitamin E/therapeutic use , Animals , Blood Glucose/metabolism , Creatinine/blood , Cyclic GMP/metabolism , Diabetes Mellitus, Experimental/drug therapy , Glutathione Transferase/blood , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Kidney/drug effects , Kidney/physiology , Male , Nitric Oxide Synthase Type II/genetics , Oxidative Stress/drug effects , Rats , Reactive Oxygen Species/metabolism , Reference Values , Urea/blood
8.
Open Cardiovasc Med J ; 2: 70-8, 2008.
Article in English | MEDLINE | ID: mdl-18949102

ABSTRACT

AIM: To investigate the possible role of oxidative stress as a common mediator of apoptosis and cardiac damage in diabetes. MATERIALS AND METHODS: This experimental work was conducted on 5 groups of Wistar rats. Group I was the control group. Diabetes type 1 was induced in other groups (by streptozotocin) and animals received insulin or vitamin E (300 mg /kg body weight), both insulin and vitamin E, or no treatment for 4 weeks according to their group. At the end of the study, serum and cardiac tissues were examined for biochemical parameters of cardiac function, oxidative stress and apoptosis. Electron microscopy pictures of cardiac tissue were also evaluated for signs of cardiac damage RESULTS: Markers of oxidative stress, apoptosis, inflammation as well as manifestations of cardiac damage as assessed by electron microscopy were significantly decreased in rats treated with both insulin and vitamin E when compared with untreated diabetic rats or rats treated with either insulin or vitamin E alone CONCLUSION: Administration of both vitamin E and insulin was effective in reducing markers of oxidative stress and apoptosis and improving parameters of cardiac function in experiments animals. Antioxidants might prove beneficial as an adjuvant treatment in addition to insulin in type 1 diabetes associated with manifestations of cardiac complications.

9.
Curr Vasc Pharmacol ; 4(3): 215-27, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16842139

ABSTRACT

Diabetes represents a serious risk factor for the development of cardiovascular problems such as coronary heart disease, peripheral arterial disease, hypertension, stroke, cardiomyopathy, nephropathy and retinopathy. Identifying the pathogenesis of this increased risk provides a basis for secondary intervention to reduce morbidity and mortality in diabetic patients. Hyperglycemia and protein glycation, increased inflammation, a prothrombotic state and endothelial dysfunction have all been implicated as possible mechanisms for such complications. A linking element between many of these phenomena could possibly be, among other factors, increased production of reactive oxygen species. Vascular endothelial cells have several physiological actions that are essential for the normal function of the cardiovascular system. These include the production of nitric oxide (NO), which regulates vasodilatation, anticoagulation, leukocyte adhesion, smooth muscle proliferation and the antioxidative capacity of endothelial cells. However, under conditions of hyperglycemia, excessive amounts of superoxide radicals are produced inside vascular cells and this can interfere with NO production leading to the possible complications. This article aims at reviewing the links between reactive oxygen species, diabetes and vascular disease and whether or not antioxidants can alter the course of vascular complications in diabetic patients and animal models. A possible beneficial effect of antioxidants might present a new addition to the range of secondary preventive measures used in diabetic patients.


Subject(s)
Cardiovascular Diseases/metabolism , Diabetes Complications/metabolism , Oxidative Stress , Animals , Antioxidants/pharmacology , Antioxidants/therapeutic use , Ascorbic Acid/pharmacology , Cardiovascular Diseases/physiopathology , Cardiovascular Diseases/prevention & control , Clinical Trials as Topic , Diabetes Complications/physiopathology , Diabetes Complications/prevention & control , Dyslipidemias/drug therapy , Dyslipidemias/metabolism , Dyslipidemias/physiopathology , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Endothelium, Vascular/physiopathology , Glucose/metabolism , Humans , Hyperglycemia/drug therapy , Hyperglycemia/metabolism , Hyperglycemia/physiopathology , Hypertension/drug therapy , Hypertension/metabolism , Hypertension/physiopathology , Insulin Resistance , Nitric Oxide/metabolism , Reactive Oxygen Species/metabolism , Risk Factors , Vitamin E/pharmacology , Vitamin E/therapeutic use , alpha-Tocopherol/pharmacology , alpha-Tocopherol/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...